TIDES USA is the flagship must-attend event in the TIDES: Oligonucleotide & Peptide Therapeutics portfolio. It is the world’s largest gathering for those interested in accelerating oligonucleotide, peptide, mRNA and genome editing products from early discovery to late-stage development and commercialization. The program features 5 concurrent tracks covering the following 6 scientific themes including in-depth discovery, development and CMC strategies, trends, and technologies across the entire spectrum of oligonucleotides, peptides, mRNA, and genome editing, with a strong focus on drug delivery strategies for these modalities.
Fill out the Form Below
Download the
TIDES USA 2027
Preliminary Agenda
TIDES USA TRACKS
Oligonucleotide Chemistry, Manufacturing & Controls
Oligonucleotide Discovery, Preclinical and Clinical
Peptide Chemistry, Manufacturing & Controls
Peptide Discovery, Preclinical and Clinical
mRNA Therapeutics/Vaccines & Genome Editing
Drug Delivery Innovations and Delivery of Macromolecules
Download the
TIDES USA 2027
Preliminary Agenda
"Attending TIDES has been a valuable experience for our team.
Beyond the high scientific quality of the presentations, the conference has provided an excellent opportunity to establish new connections with technology providers and potential development partners in the oligonucleotide field. The yearly TIDES conferences are among the most important events within peptide and oligonucleotide discovery and development and it has always been among my high priority to be able to join them."
- Ömer Faruk Fırat, R&D Director, Polifarma
"TIDES has consistently been a key annual event for the peptide and oligonucleotide community.
I keep attending because it provides an excellent opportunity to follow market trends, identify emerging concepts and technologies, and connect with industry leaders. With the current situation facing the world with the Covid-19 pandemic, we fully support the digital format that is being offered for the TIDES meeting(s). The digital format will still allow AmbioPharm to reach out to our existing as well as new potential clients. This is the right decision for all of us."
- Olivier Ludemann-Hombourger, Director Global, Innovation & Technology, Polypeptide Laboratories France S.A.S
